Targets › CHKA
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Other, Psychiatry, Oncology; next expected readout Jul 2027.
Plays a key role in phospholipid biosynthesis by catalyzing the phosphorylation of free choline to phosphocholine, the first step in phosphatidylcholine biosynthesis. Also phosphorylates ethanolamine, thereby contributing to phosphatidylethanolamine biosynthesis. (UniProt, P35790)
Open in Phaseline: the race on CHKA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Andrei Iagaru | 18F Fluorocholine Fluorine-18 labeled choline PET tracer | CHKA | Phase 2 | Parathyroid Adenoma | Jul 2027 |
| Jeff Wozniak | Choline Bitartrate Choline supplementation, a precursor for acetylcholine and phosphatidylcholine synthesis | CHKA | Phase 2 | Fetal Alcohol Spectrum Disorders | Jul 2027 |
| University of Colorado, Denver | Choline (Phosphatidylcholine) Choline/phosphatidylcholine supplementation to support fetal brain development | CHKA | Phase 1 | Child Development | Apr 2029 |
Fetal Alcohol Spectrum Disorders (1) Child Development (1) Parathyroid Adenoma (1)
small molecule (2), mixed (1)
Jeff Wozniak (1) University of Colorado, Denver (1) Andrei Iagaru (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.